SGLT-2 inhibitors in patients with and without a history of heart failure: a meta-analysis

Back

ESC Premium Access

SGLT-2 inhibitors in patients with and without a history of heart failure: a meta-analysis

Session: Congress committee e-posters choice in heart failure

Topic: Pharmacotherapy

Speaker: Doctor V. Razuk (New York, US)

Event: ESC Congress 2021 - The Digital Experience

Congress Presentation

Add to my library

About the speaker

Doctor Victor Razuk

Icahn School of Medicine at Mount Sinai, New York (United States of America)

0 follower

46 more presentations in this session

Impact of changes in weight and haematocrit on the reduction in systolic office and ambulatory blood pressure with empagliflozin in patients with type 2 diabetes

Speaker: Doctor A. Sharma (Montreal, CA)

Access

Abstract

Slides

Cardiovascular outcome in patients treated with SGLT2 inhibitors for heart failure: a meta-analysis

Speaker: Doctor G. Steiner-Gager (Vienna, AT)

Access

Abstract

Slides

Reduced tissue sodium content is related to improvement of vascular function in patients with chronic heart failure treated with the SGLT2 inhibitor empagliflozin

Speaker: Doctor J. Kolwelter (Erlangen, DE)

Access

Abstract

Slides

Efficacy and safety of vericiguat in patients with HFrEF treated with sacubitril/valsartan: results from the VICTORIA trial

Speaker: Doctor M. Senni (Bergamo, IT)

Access

Abstract

Slides

Empagliflozin reduces TNFa-induced reactive oxygen species through inhibition of the human endothelial Na+/H+ exchanger 1

Speaker: Doctor L. Uthman (Nijmegen, NL)

Access

Abstract

Slides

Access the full session

Congress committee e-posters choice in heart failure

Speakers: Doctor V. Razuk, Doctor A. Sharma, Doctor G. Steiner-Gager, Doctor J. Kolwelter, Doctor M. Senni...

Access

About the event

ESC Congress 2021 - The Digital Experience

27 August - 30 August 2021

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources